CDSCO Panel grants Pfizer’s Protocol Amendment for Anti-cancer Drug Palbociclib study
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Pfizer’s protocol amendment proposal for the the clinical trial titled ” Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors”. This came after the drug maker Pfizer presented protocol amendment […]